News | Women's Health | December 07, 2015

iCAD Featured New Technology for Automated Breast Density Assessment and Showcased Solutions for Tomosynthesis at RSNA 2015

iCAD demonstrated iReveal breast density assessment for 2-D and tomosynthesis mammography, PowerLook Advanced Mammography Platform and VeraLook colon polyp detection technology

iCAD Featured New Technology for Automated Breast Density Assessment and Showcased Solutions for Tomosynthesis at RSNA 2015

December 7, 2015 — iCAD, Inc. featured its latest solutions for advanced image analysis and workflow tools for the early identification of cancer at the Radiological Society of North American (RSNA) 2015 Annual Meeting in Chicago. The company showcased recent product advances including iReveal, an automated breast density assessment solution, PowerLook Advanced Mammography Platform, featuring the company’s flagship advanced cancer detection product, VeraLook colon polyp detection technology and new tomosynthesis solutions, shown as works in progress.  

The iReveal automated breast density solution is designed to standardize the assessment and reporting of breast density. iReveal assists radiologists in evaluating and scoring breast density to identify patients who may be at higher risk of developing breast cancer. With an appearance-based approach, iReveal uses an innovative technique that analyzes the structure, texture, and dispersion of the fibroglandular tissue in the breast, then calibrates the results to a density category corresponding to the BI-RADS breast density reporting system. iCAD will also be previewing a breast density assessment solution for tomosynthesis.

“The issue of breast density is rapidly emerging as a pivotal factor in the diagnosis of breast cancer, and iReveal is another great example of our continued focus to detect cancer earlier, when it may be more easily treated,” said Ken Ferry, CEO of iCAD. “Currently, 24 states have adopted legislation that require patients to be notified of their breast density.  As these laws expand to other states and perhaps nationally, it is essential for radiologists to have access to superior technology that delivers rapid, automatic, and reproducible breast density assessment results.”

The PowerLook AMP solution delivers superior performance for accurate detection of breast cancer.  VeraLook automatically detects polyps in computed tomography colonography (CTC) images assisting in the interpretation of CTC exams. As a work in progress, iCAD also be demonstratied tomosynthesis workflow tools to support cancer detection and increased reading efficiency.

“This has been an exciting year at iCAD where our focus on innovation and product development have delivered some important advances that will significantly improve cancer diagnosis and treatment in the years ahead,” Ferry added.

For more information: www.icadmed.com

Related Content

Researchers developed a deep learning model that identifies imaging biomarkers to predict a patient’s risk for developing breast cancer

A deep learning model was developed that combined imaging and traditional risk factors.

News | Mammography | November 30, 2020
November 30, 2020 — Researchers at Massachusetts General Hospi...
 Lunit, a leading medical AI software company, will be joining the 106th Radiological Society of North America (RSNA) this year, presenting its AI solutions for chest X-ray and mammography at partner booths.
News | Artificial Intelligence | November 24, 2020
November 24, 2020 — Lunit, a leading medical AI software company, will be joining the 106th...
ProFound AI for DBT offers superior clinical performance when compared to other commercially available breast AI systems
News | Breast Imaging | November 24, 2020
November 24, 2020 — iCAD reported that over 1,000 licenses have been sold as part of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...